Biocon Biologics secures market entry date for denosumab biosimilars in Europe and RoW: Our Bureau, Mumbai Tuesday, December 2, 2025, 15:15 Hrs [IST] Biocon Biologics Ltd. (BBL), ...
EO2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastoma Enterome, a clinical-stage company pioneering OncoMimics™ peptides, a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback